●“Searching for new targets for sporadic ALS using AI: Let’s become friends with AI”
Currently, over 20,000 genes have been reported in humans. However, in fact, only a small number of genes are discussed in the literature as being related to diseases. It is said that one of the reasons for this is the confirmation bias of researchers. In other words, many researchers are working hard to demonstrate their uniqueness within extremely limited information.
FRONTEO's proprietary natural language processing AI engine, KIBIT, provides unbiased hints for drug discovery targets from information on over 3000 million papers. This time, we will introduce an example of searching for a new target for sporadic ALS from the perspective of ``how to extract hints about new targets while talking with AI.''

●“Enhancement of AI drug discovery support service: Utilizing Springer Nature’s 600 journal data”
It is currently extremely difficult for drug discovery researchers to discover target molecules with unreported association with disease. At the FRONTEO Drug Discovery AI Factory, biologists who have extensive drug discovery experience cultivated at major pharmaceutical companies and international research institutes and a deep understanding of AI utilize in-house developed natural language processing AI and use their own analysis methods.By using this, it has become possible to propose multiple highly novel target genes and their hypotheses in a short period of time.
We will introduce support for significantly improving the efficiency, acceleration, and success rate of drug discovery research through the fusion of AI and biologists.
This month we also announced the launch of a new service that analyzes 600 Springer Nature journals. We will also inform you about the enhanced Drug Discovery AI Factory functionality.

[Date and time] Thursday, November 2024, 3 28:12~00:13

[Format] Online (Zoom Webinars)

[Participation conditions]
We kindly ask that you refrain from applying if you are using the free address, if you are in the same industry as us, or if you do not know your affiliation.When accessing Zoom on the day, please enter your name and email address that you entered at the time of application in the entry field for Zoom participation.

FRONTEO Inc.
Executive Officer Drug Discovery AI Factory Executive Officer
Head of Life Science AI Business Headquarters and Director of Behavioral Information Science Research Institute
CTO Ph.D. (Science)
Hiroyoshi Toyoshiba

Waseda University Graduate School of Science and Engineering Department of Mathematics.Since 2000, during the doctoral course in science (mathematics, obtained a doctorate in 1999), he has been in charge of statistical analysis of medical data at the Medical Information Department of Kyushu University Hospital. Since 2000, he has participated in research on carcinogenic processes by data analysis at the National Institute of Environmental Health Sciences (NIEHS). Since 2004, he has been engaged in statistical analysis of toxicity data, design of epidemiological research, and data analysis research at the National Institute for Environmental Studies. Joined Takeda Pharmaceutical Company Limited in 2006, and has served as a researcher in the field of bioinformatics, head of the Global Data Science Institute / Japan Site Bioinformatics, and a science fellow.He is also involved in gene expression data analysis and target search in clinical trial data, as well as biomarker search in immunity and cancer.
Engaged in life science AI development at FRONTEO since 2017.He develops AI algorithms specialized in the area of ​​life sciences.Utilizing the feature of vectorization of text, we have developed various AI products based on this artificial intelligence, such as research paper search, drug discovery support, dementia diagnosis support, and fall prediction.
Life Science AI CTO since 2019. In 2021, he will be appointed as an executive officer.Further promote the social implementation of AI through a mathematical approach.

FRONTEO Inc.
Manager, Life Science AI Research Team, Life Science AI Business Headquarters
Ph.D. (Pharmacy)
Kazumi Hayashi

After obtaining a doctorate in pharmaceutical sciences, he joined Yamanouchi Pharmaceutical (currently Astellas Pharma).He is active as a research manager in the fields of inflammation, cardiovascular systems, and kidneys.He established the Drug Repurposing Laboratory and engaged in DR research. He is in charge of devising analysis methods using KIBIT, planning analysis policies, analysis, and hypothesis generation.